Takeda Pharmaceutical

Takeda 4QFY22: Top Line Expands and Pipeline Development Progresses Despite OP Drop

Equity Bottom-Up
196 Views, 12 May 2022 19:08
EXECUTIVE SUMMARY
  • Takeda Pharmaceutical (4502 JP) reported 4QFY03/2022 results yesterday. Reported revenue grew 13.4% YoY to JPY873.3bn (vs consensus JPY825.7bn) while the company reported operating losses of JPY1.7bn.
  • Revenue from Top 14 drugs grew 20.3% YoY, while revenue from top-seller Entyvio grew 15.0% YoY during the quarter. Excluding Entyvio, other top 13 drugs grew 23.3% during the period.
  • Takeda’s shares moved down 2.0% at the end of yesterday’s trading and down 3% during today’s trade as profit drop disappointed the market.
detail (5-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Top 5%
Shifara Samsudeen, ACMA, CGMA
Equity Analyst
LightStream Research
JapanIndustrialsEquity Bottom-UpEquity Capital Markets

A chartered management accountant with more than 10 years of rich experience in investment research and financial analys... 

Zoom:
NaN%
x